At the European Society of Cardiology conference on Sunday, Johnson & Johnson (NYSE:JNJ) presented disappointing results from its MARINER study evaluating the use …
Cowen’s Phil Nadeau takes the FDA victory for Portola in bullish stride, betting on broad adoption kicking off next year.
Oppenheimer’s Jay Olson still sees 106% return potential for PTLA shares after dialing back the price target.
